Directed share issue in Herantis Pharma Plc (FI) — EUR 6.8 million

Carnegie acted as sole global co-ordinator and sole bookrunner in the directed new share issue of 875,000 shares at a subscription price of EUR 7.80 per share. Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches. Herantis’ regenerative medicine drug candidates, CDNF and Lymfactin®, aim to revolutionize the treatment of Parkinson’s disease and other neurodegenerative diseases as well as secondary lymphedema. May 2020.